Skip to content
OpenCapital
Get started

Enanta Pharmaceuticals ENTA Q4 2024 earnings

Reported February 10, 2025 · Before market open

Revenue$17.0MMiss by $290.3K
EPS-$1.05Beat by $0.11
Revenue estimate$17.2M
EPS estimate-$1.16

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$16.8M
EPS estimate-$0.51

Versus estimates

Revenue

Q1 2026$17.2MBeat by $131.7KQ4 2025$18.6MBeat by $2.7MQ3 2025$15.1MMiss by $845.6KQ2 2025$18.3MBeat by $2.3MQ1 2025$14.9MMiss by $1.0M
Q4 2024$17.0MMiss by $290.3K

Diluted EPS

Q1 2026-$0.45Beat by $0.01Q4 2025-$0.42Beat by $0.12Q3 2025-$0.87Beat by $0.26Q2 2025-$0.85Beat by $0.40Q1 2025-$1.06Miss by $0.02
Q4 2024-$1.05Beat by $0.11

Ask the moment Enanta Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Enanta Pharmaceuticals report Q4 2024 earnings?
Enanta Pharmaceuticals (ENTA) reported Q4 2024 earnings on February 10, 2025 before market open.
What were Enanta Pharmaceuticals's Q4 2024 revenue and EPS?
Enanta Pharmaceuticals reported revenue of $17.0M and eps of $-1.05 for Q4 2024.
Did Enanta Pharmaceuticals beat estimates in Q4 2024?
Revenue missed the consensus estimate of $17.2M by $290.3K. EPS beat the consensus estimate of $-1.16 by $0.11.
Where can I find Enanta Pharmaceuticals's Q4 2024 SEC filings?
You can read the 10-Q periodic report (0000950170-25-018810) directly on SEC EDGAR. The filing index links above go to sec.gov.